AIM
AIM ImmunoTech Inc.
Biotechnology
Market Cap$31M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AIM vs INO
Revenue, margins, valuation, and 5-year total return — side by side.
INO
Inovio Pharmaceuticals, Inc.
Biotechnology
Market Cap$642M
5Y Perf.-99.2%
AIM vs INO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AIM | INO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $31M | $642M |
| Revenue (TTM) | $112K | $0.00 |
| Net Income (TTM) | $-16M | $-84.95B |
| Gross Margin | 18.8% | — |
| Operating Margin | -129.3% | — |
| Total Debt | $3M | $9.37B |
| Cash & Equiv. | $2M | $44.27B |
AIM vs INO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AIM
INO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | 100 | 0.2 | -99.8% |
| Inovio Pharmaceutic… (INO) | 100 | 0.8 | -99.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIM vs INO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AIM leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Inovio Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AIM
AIM ImmunoTech Inc.
The Income Pick
AIM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.09
- Rev growth -15.8%, EPS growth 48.3%, 3Y rev CAGR 8.0%
- Lower volatility, beta 1.09, current ratio 0.44x
Best for: income & stability and growth exposure
INO
Inovio Pharmaceuticals, Inc.
The Long-Run Compounder
INO is the clearest fit if your priority is long-term compounding.
- -98.6% 10Y total return vs AIM's -100.0%
- -22.2% vs AIM's -94.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AIM | -15.8% revenue growth vs INO's -100.0% |
| Stability / Safety | AIM | Beta 1.09 vs INO's 1.31 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INO | -22.2% vs AIM's -94.6% |
| Efficiency (ROA) | AIM | -286.7% ROA vs INO's -455.9% |
AIM vs INO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
AIM vs INO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAIMLAGGINGINO
INOInovio Pharmaceutical…
1leads
AIMAIM ImmunoTech Inc.
2leads
6 Total Categories
CATEGORYLEADERvs INOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
AIM1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AIM5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
INO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — AIM and INO each lead in 1 of 2 comparable metrics.
Income & Cash Flow (Last 12 Months)
AIM and INO operate at a comparable scale, with $112,000 and $0 in trailing revenue. On growth, AIM holds the edge at -25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $112,000 | $0 |
| EBITDAEarnings before interest/tax | -$14M | -$86.8B |
| Net IncomeAfter-tax profit | -$16M | -$84.9B |
| Free Cash FlowCash after capex | -$13M | -$19.4B |
| Gross MarginGross profit ÷ Revenue | +18.8% | — |
| Operating MarginEBIT ÷ Revenue | -129.3% | — |
| Net MarginNet income ÷ Revenue | -140.6% | — |
| FCF MarginFCF ÷ Revenue | -119.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.7% | -155.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.5% | +1036.4% |
Evenly matched — AIM and INO each lead in 1 of 2 comparable metrics.
Valuation Metrics
AIM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| Market CapShares × price | $31M | $642M |
| Enterprise ValueMkt cap + debt − cash | $33M | -$34.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.81x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 184.53x | — |
| Price / BookPrice ÷ Book value/share | — | 0.03x |
| Price / FCFMarket cap ÷ FCF | — | — |
AIM leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
AIM leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
AIM delivers a -3.9% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-14 for INO. On the Piotroski fundamental quality scale (0–9), AIM scores 3/9 vs INO's 0/9, reflecting mixed financial health.
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | -14.1% |
| ROA (TTM)Return on assets | -2.9% | -4.6% |
| ROICReturn on invested capital | -5.5% | — |
| ROCEReturn on capital employed | -4.0% | -5.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 0 |
| Debt / EquityFinancial leverage | — | 0.39x |
| Net DebtTotal debt minus cash | $1M | -$34.9B |
| Cash & Equiv.Liquid assets | $2M | $44.3B |
| Total DebtShort + long-term debt | $3M | $9.4B |
| Interest CoverageEBIT ÷ Interest expense | -27.48x | — |
AIM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
INO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INO five years ago would be worth $167 today (with dividends reinvested), compared to $29 for AIM. Over the past 12 months, INO leads with a -22.2% total return vs AIM's -94.6%. The 3-year compound annual growth rate (CAGR) favors INO at -48.4% vs AIM's -77.0% — a key indicator of consistent wealth creation.
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -52.9% | -18.9% |
| 1-Year ReturnPast 12 months | -94.6% | -22.2% |
| 3-Year ReturnCumulative with dividends | -98.8% | -86.2% |
| 5-Year ReturnCumulative with dividends | -99.7% | -98.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -98.6% |
| CAGR (3Y)Annualised 3-year return | -77.0% | -48.4% |
INO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AIM and INO each lead in 1 of 2 comparable metrics.
Risk & Volatility
AIM is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than INO's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INO currently trades 46.0% from its 52-week high vs AIM's 2.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 1.31x |
| 52-Week HighHighest price in past year | $19.15 | $2.98 |
| 52-Week LowLowest price in past year | $0.46 | $1.03 |
| % of 52W HighCurrent price vs 52-week peak | +2.9% | +46.0% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 50.9 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 1.9M |
Evenly matched — AIM and INO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | AIMAIM ImmunoTech In… | INOInovio Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $6.00 |
| # AnalystsCovering analysts | — | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AIM leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). INO leads in 1 (Total Returns). 2 tied.
Best OverallAIM ImmunoTech Inc. (AIM)Leads 2 of 6 categories
Loading custom metrics...
AIM vs INO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AIM or INO a better buy right now?
For growth investors, AIM ImmunoTech Inc.
(AIM) is the stronger pick with -15. 8% revenue growth year-over-year, versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). Analysts rate Inovio Pharmaceuticals, Inc. (INO) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIM or INO?
Over the past 5 years, Inovio Pharmaceuticals, Inc.
(INO) delivered a total return of -98. 3%, compared to -99. 7% for AIM ImmunoTech Inc. (AIM). Over 10 years, the gap is even starker: INO returned -98. 6% versus AIM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIM or INO?
By beta (market sensitivity over 5 years), AIM ImmunoTech Inc.
(AIM) is the lower-risk stock at 1. 09β versus Inovio Pharmaceuticals, Inc. 's 1. 31β — meaning INO is approximately 21% more volatile than AIM relative to the S&P 500.
04Which is growing faster — AIM or INO?
By revenue growth (latest reported year), AIM ImmunoTech Inc.
(AIM) is pulling ahead at -15. 8% versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). On earnings-per-share growth, the picture is similar: Inovio Pharmaceuticals, Inc. grew EPS 54. 2% year-over-year, compared to 48. 3% for AIM ImmunoTech Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AIM or INO?
Inovio Pharmaceuticals, Inc.
(INO) is the more profitable company, earning 0. 0% net margin versus -101. 9% for AIM ImmunoTech Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INO leads at 0. 0% versus -116. 3% for AIM. At the gross margin level — before operating expenses — AIM leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AIM or INO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AIM or INO better for a retirement portfolio?
For long-horizon retirement investors, AIM ImmunoTech Inc.
(AIM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (AIM: -100. 0%, INO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AIM and INO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AIM: -25.7% · INO: -155.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.